摘要
通过对野山参的资源、商品种质构成 ,以及相关生药学研究和质量标准等情况的分析 ,认为野山参为国家濒危保护物种 ,应严格限制使用直至禁用 ,建议《中国药典》[1] 作相应修订。市场上流通的野山参绝大部分是各种人工培育成的半野生人参的加工品 ,其药品名称均为人参。现行的其它有关标准中所涉及的野山参真伪鉴别应属于商品规格等级鉴定 ,是商品流通所需。各种培育山参可通过注册商标或申请原产地域保护取得法律保障。
By analyzing the resource, merchant classifications, relevant quality and the pharmacognosy situation, the authors suggested wild Ginseng be regarded as protection species in severe danger, and the use be strictly restricted, even forbidden. The authors also suggested to draft a new quality specification for wild Ginseng in China Pharmacopoeia to differentiate most merchant Ginseng which are artificial cultured half-wild Ginseng, including up-bring Ginseng. The Quality specification for wild Ginseng and the merchant degree of artificial cultured Ginseng should be separated. Cultured Ginseng can be legally protected by trademark registration and origin producing area registration.
出处
《中国药事》
CAS
2003年第12期765-768,共4页
Chinese Pharmaceutical Affairs
关键词
野山参
生晒山参
培育山参
质量标准
商品规格
wild Ginseng, up-bring wild Ginseng
artificial cultured Ginseng, Quality specification, trademark
